

Waldemar Priebe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10432053/publications.pdf>

Version: 2024-02-01

156
papers

6,887
citations

53751

45
h-index

69214

77
g-index

156
all docs

156
docs citations

156
times ranked

8767
citing authors

#	ARTICLE	IF	CITATIONS
1	Glioma cancer stem cells induce immunosuppressive macrophages/microglia. <i>Neuro-Oncology</i> , 2010, 12, 1113-1125.	0.6	530
2	2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo. <i>Cancer Research</i> , 2004, 64, 31-34.	0.4	414
3	A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients. <i>Cancer Research</i> , 2007, 67, 9630-9636.	0.4	278
4	Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 67-78.	1.9	253
5	Parsing the Free Energy of Anthracycline Antibiotic Binding to DNA. <i>Biochemistry</i> , 1996, 35, 2047-2053.	1.2	187
6	Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium. <i>Stem Cells</i> , 2009, 27, 857-865.	1.4	182
7	Hypoxia Potentiates Glioma-Mediated Immunosuppression. <i>PLoS ONE</i> , 2011, 6, e16195.	1.1	177
8	The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas. <i>Clinical Cancer Research</i> , 2008, 14, 8228-8235.	3.2	174
9	Structure-Based Design of a New Bisintercalating Anthracycline Antibiotic. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 261-266.	2.9	150
10	WP1066 Disrupts Janus Kinase-2 and Induces Caspase-Dependent Apoptosis in Acute Myelogenous Leukemia Cells. <i>Cancer Research</i> , 2007, 67, 11291-11299.	0.4	127
11	Mitotic Catastrophe Results in Cell Death by Caspase-Dependent and Caspase-Independent Mechanisms. <i>Cell Cycle</i> , 2006, 5, 53-60.	1.3	123
12	Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. <i>Biochemical Pharmacology</i> , 2007, 73, 620-631.	2.0	118
13	Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. <i>Cancer</i> , 2011, 117, 2926-2938.	2.0	112
14	A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells. <i>Clinical Cancer Research</i> , 2008, 14, 5759-5768.	3.2	111
15	Ultratight DNA Binding of a New Bisintercalating Anthracycline Antibiotic. <i>Biochemistry</i> , 1998, 37, 1743-1753.	1.2	109
16	Quantitative Phosphoproteomic Analysis of the STAT3/IL-6/HIF1 α Signaling Network: An Initial Study in GSC11 Glioblastoma Stem Cells. <i>Journal of Proteome Research</i> , 2010, 9, 430-443.	1.8	99
17	A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. <i>Investigational New Drugs</i> , 2007, 25, 313-326.	1.2	89
18	Synthesis of alkyl 4,6-di-o-acetyl-2,3-dideoxy- β -d-threo-hex-2-enopyranosides from 3,4,6-tri-o-acetyl-1,5-anhydro-2-deoxy- β -d-lyxo-hex-1-enitol (3,4,6-tri-o-acetyl-d-galactal). <i>Carbohydrate Research</i> , 1979, 68, 33-41.	1.1	85

#	ARTICLE	IF	CITATIONS
19	Evidence that activation of nuclear factor- κ B is essential for the cytotoxic effects of doxorubicin and its analogues. <i>Biochemical Pharmacology</i> , 2004, 67, 353-364.	2.0	83
20	Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. <i>Blood</i> , 2007, 109, 3470-3478.	0.6	82
21	Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). <i>Biochemical Pharmacology</i> , 2002, 64, 1745-1751.	2.0	77
22	Inhibition of the JAK2/STAT3 Pathway Reduces Gastric Cancer Growth In Vitro and In Vivo. <i>PLoS ONE</i> , 2014, 9, e95993.	1.1	77
23	Doxorubicin- and Daunorubicin-Glutathione Conjugates, but Not Unconjugated Drugs, Competitively Inhibit Leukotriene C4Transport Mediated byMRP/GS-XPump. <i>Biochemical and Biophysical Research Communications</i> , 1998, 247, 859-863.	1.0	76
24	WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation. <i>Clinical Cancer Research</i> , 2008, 14, 788-796.	3.2	76
25	A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1023-1032.	2.0	74
26	Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. <i>Neuro-Oncology</i> , 2012, 14, 1136-1145.	0.6	73
27	The Overall Partitioning of Anthracyclines into Phosphatidyl-Containing Model Membranes Depends Neither on the Drug Charge Nor the Presence of Anionic Phospholipids. <i>FEBS Journal</i> , 1996, 241, 879-887.	0.2	72
28	Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses. <i>Clinical Cancer Research</i> , 2010, 16, 5722-5733.	3.2	71
29	Efficacy of 2-halogen substituted d-glucose analogs in blocking glycolysis and killing hypoxic tumor cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 725-734.	1.1	67
30	Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. <i>Anti-Cancer Drugs</i> , 1993, 4, 37-48.	0.7	66
31	Binding of Two Novel Bisdaunorubicins to DNA Studied by NMR Spectroscopy. <i>Biochemistry</i> , 1997, 36, 8663-8670.	1.2	66
32	In Vitro Evaluation of Photosensitivity Risk Related to Genetic Polymorphisms of Human ABC Transporter ABCG2 and Inhibition by Drugs. <i>Drug Metabolism and Pharmacokinetics</i> , 2007, 22, 428-440.	1.1	66
33	Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. <i>Journal of Neuro-Oncology</i> , 2012, 107, 487-501.	1.4	64
34	The acid-catalysed reaction of thiols with alkyl 2,3-dideoxy-glyc-2-enopyranosides or glycols. <i>Tetrahedron</i> , 1980, 36, 287-297.	1.0	63
35	Structure of a DNA~Bisdaunomycin Complex. <i>Biochemistry</i> , 1997, 36, 5940-5946.	1.2	60
36	Iodoalkoxylation of 1,5-anhydro-2-deoxy-hex-1-enitols (glycols). <i>Carbohydrate Research</i> , 1990, 205, 71-86.	1.1	59

#	ARTICLE	IF	CITATIONS
37	Analysis of Drug Transport Kinetics in Multidrug-resistant Cells: Implications for Drug Action. <i>Current Medicinal Chemistry</i> , 2001, 8, 51-64.	1.2	59
38	Base Specific and Regioselective Chemical Cross-Linking of Daunorubicin to DNA. <i>Journal of the American Chemical Society</i> , 1996, 118, 4731-4738.	6.6	55
39	Allylic rearrangement of 6-deoxyglycals having practical utility. <i>Carbohydrate Research</i> , 1985, 144, 331-337.	1.1	53
40	A New Bisintercalating Anthracycline with Picomolar DNA Binding Affinity. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 8209-8219.	2.9	53
41	Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approach. , 1993, 60, 215-234.		51
42	Degrasynt Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells <i>in vitro</i> and <i>in vivo</i> : Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2026-2036.	1.9	51
43	Inhibition of p-STAT3 Enhances IFN- γ Efficacy against Metastatic Melanoma in a Murine Model. <i>Clinical Cancer Research</i> , 2010, 16, 2550-2561.	3.2	51
44	Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. <i>Oncotarget</i> , 2015, 6, 10016-10029.	0.8	50
45	IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw182.	3.0	49
46	Analysis of the Effects of Daunorubicin and WP631 on Transcription. <i>Current Medicinal Chemistry</i> , 2001, 8, 1-8.	1.2	46
47	The Inhibitory Effect of 2-Halo Derivatives of d-Glucose on Glycolysis and on the Proliferation of the Human Malaria Parasite <i>Plasmodium falciparum</i> . <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 511-517.	1.3	45
48	Synthetic routes to higher-carbon sugars. Reaction of lactones with 2-lithio-,3-dithiane. <i>Carbohydrate Research</i> , 1981, 94, 27-41.	1.1	43
49	Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1999, 1450, 374-384.	1.9	42
50	Differential Sensitivity to 2-Deoxy-D-glucose Between Two Pancreatic Cell Lines Correlates With GLUT-1 Expression. <i>Pancreas</i> , 2005, 30, e34-e39.	0.5	40
51	Effect of vesicle size and lipid composition on their <i>in vivo</i> tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes. <i>International Journal of Cancer</i> , 1995, 61, 666-671.	2.3	39
52	Interaction of doxorubicin and its derivatives with DNA: Elucidation by resonance Raman and surface-enhanced resonance Raman spectroscopy. <i>Biospectroscopy</i> , 1997, 3, 307-316.	0.7	39
53	A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. <i>Cellular Signalling</i> , 2011, 23, 2076-2085.	1.7	38
54	Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. <i>Clinical Cancer Research</i> , 2020, 26, 4983-4994.	3.2	38

#	ARTICLE	IF	CITATIONS
55	New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. <i>Chemico-Biological Interactions</i> , 2003, 145, 349-358.	1.7	37
56	The tumor microenvironment expression of pSTAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. <i>International Journal of Cancer</i> , 2012, 131, 8-17.	2.3	36
57	10 tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. <i>Biochemical Pharmacology</i> , 2000, 60, 1897-1905.	2.0	35
58	Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 657-670.	1.5	35
59	P-Glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. <i>FEBS Journal</i> , 2001, 268, 1561-1567.	0.2	34
60	Glycomic and Transcriptomic Response of GSC11 Glioblastoma Stem Cells to STAT3 Phosphorylation Inhibition and Serum-Induced Differentiation. <i>Journal of Proteome Research</i> , 2010, 9, 2098-2108.	1.8	34
61	Induction of G2/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes. <i>Biochemical Pharmacology</i> , 2002, 63, 1251-1258.	2.0	32
62	Regulation of HGF Expression by EGFR-Mediated c-Met Activation in Glioblastoma Cells. <i>Neoplasia</i> , 2013, 15, 73-IN21.	2.3	32
63	How Does the MRP/CS-X Pump Export Doxorubicin?. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1639-1640.	3.0	31
64	Halogenation of 1,5-anhydrohex-1-enitols (glycals). Influence of the C-6 substituent. <i>Journal of Organic Chemistry</i> , 1986, 51, 3479-3485.	1.7	29
65	Exploiting anthracycline scaffold for designing DNA-targeting agents. <i>Methods in Enzymology</i> , 2001, 340, 529-555.	0.4	29
66	Synthesis and antitumor activity of 3'-deamino-3'-hydroxydoxorubicin. A facile procedure for the preparation of doxorubicin analogs.. <i>Journal of Antibiotics</i> , 1984, 37, 853-858.	1.0	28
67	Synthesis and antitumor activity of 7-O-(3,4-di-O-acetyl-2,6-dideoxy-1-H-xylo-hexopyranosyl)adriamycinone. <i>Carbohydrate Research</i> , 1981, 94, 11-25.	1.1	26
68	Therapeutic suppression of constitutive and inducible JAK/STAT activation in head and neck squamous cell carcinoma. <i>Journal of Experimental Therapeutics and Oncology</i> , 2009, 8, 117-27.	0.5	25
69	Sp1-Targeted Inhibition of Gene Transcription by WP631 in Transfected Lymphocytes. <i>Biochemistry</i> , 2004, 43, 7584-7592.	1.2	24
70	Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma. <i>Tissue Engineering - Part A</i> , 2017, 23, 80-89.	1.6	24
71	Selective silylation of 6-deoxyglycals. <i>Carbohydrate Research</i> , 1985, 144, 325-330.	1.1	23
72	Oxyhalogenation of glycals for the synthesis of anti-tumor-active 2-halo daunorubicin analogs. <i>Carbohydrate Research</i> , 1985, 136, 391-396.	1.1	23

#	ARTICLE	IF	CITATIONS
73	P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. <i>FEBS Letters</i> , 1994, 356, 287-290.	1.3	23
74	Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers. <i>Recent Patents on CNS Drug Discovery</i> , 2008, 3, 179-188.	0.9	23
75	Selective acylation of 6-deoxyglycals. <i>Carbohydrate Research</i> , 1985, 144, 317-324.	1.1	22
76	A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. <i>FEBS Journal</i> , 2003, 270, 764-770.	0.2	22
77	2-Deoxy-1-O-silylated- β -hexopyranoses. Useful glycosyl donors and synthetic intermediates.. <i>Tetrahedron Letters</i> , 1991, 32, 2079-2082.	0.7	21
78	d-Glucose- and d-mannose-based antimetabolites. Part 2. Facile synthesis of 2-deoxy-2-halo-d-glucoses and -d-mannoses. <i>Carbohydrate Research</i> , 2009, 344, 1464-1473.	1.1	21
79	Therapeutic targets in subependymoma. <i>Journal of Neuroimmunology</i> , 2014, 277, 168-175.	1.1	21
80	Synthesis of antitumor-active (7S,9S)-4-demethoxy-7-O-(2,6-dideoxy-2-iodo- β -l-mannopyranosyl)adriamycinone: Preparative resolution of a racemic anthracyclinone by alkoxyhalogenation of a glycal. <i>Carbohydrate Research</i> , 1984, 130, C1-C3.	1.1	20
81	Synthesis and antitumor activity of 2-bromo- and 2-chloro-3-acetoxy-3-deaminodaunorubicin analogs. <i>Carbohydrate Research</i> , 1985, 144, 305-315.	1.1	20
82	Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. <i>Biochemical Pharmacology</i> , 2007, 73, 934-942.	2.0	20
83	d-Glucose and d-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated d-glucose, d-mannose, and 2-deoxy-d-glucose. <i>Carbohydrate Research</i> , 2013, 368, 111-119.	1.1	19
84	WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). <i>Anticancer Research</i> , 2005, 25, 1841-50.	0.5	19
85	3'-Deamino-4'-epi-3'-hydroxy-daunorubicin and -doxorubicin. Synthesis and antitumor activity.. <i>Journal of Antibiotics</i> , 1984, 37, 1635-1641.	1.0	18
86	Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 190-196.	1.1	18
87	Steric and conformational effects in the dehalogenation of 2-halo sugar derivatives with tributylstannane. <i>Journal of Organic Chemistry</i> , 1993, 58, 1821-1826.	1.7	18
88	Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. <i>International Journal of Cancer</i> , 1997, 71, 35-41.	2.3	18
89	Transcriptional changes facilitate mitotic catastrophe in tumour cells that contain functional p53. <i>European Journal of Pharmacology</i> , 2006, 540, 34-45.	1.7	18
90	Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 39, 103-108.	1.1	17

#	ARTICLE	IF	CITATIONS
91	Importance of Sp1 consensus motifs in the MYCN promoter. <i>Surgery</i> , 2002, 132, 232-238.	1.0	17
92	Preferential efflux by P-glycoprotein, but not MRP1, of compounds containing a free electron donor amine. <i>Biochemical Pharmacology</i> , 2002, 63, 1471-1479.	2.0	17
93	Integrative Biological Analysis For Neuropsychopharmacology. <i>Neuropsychopharmacology</i> , 2014, 39, 5-23.	2.8	17
94	A facile method for preparation of 3-thio-sugars and 3-thio-glycals. synthesis of 3-mercapto-3-deamino-doxorubicin. <i>Tetrahedron Letters</i> , 1991, 32, 3313-3316.	0.7	16
95	Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. <i>International Journal of Cancer</i> , 1994, 58, 85-94.	2.3	15
96	Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 109-118.	1.1	15
97	Hydroxylation at C-3 of doxorubicin alters the selected phenotype of cellular drug resistance. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5, 1807-1812.	1.0	15
98	Differential toxic effect of cis-platinum(II) and palladium(II) chlorides complexed with methyl 3,4-diamine-2,3,4,6-tetra-deoxy- β -L-lyxo-hexopyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability. <i>Teratogenesis, Carcinogenesis, and Mutagenesis</i> , 2003, 23, 1-11.	0.8	15
99	Effect of structural modification at the 4, 3, and 2 positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2007, 55, 193-198.	1.0	15
100	A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1033-1044.	1.1	15
101	Hyperpolarized Pyruvate MR Spectroscopy Depicts Glycolytic Inhibition in a Mouse Model of Glioma. <i>Radiology</i> , 2019, 293, 168-173.	3.6	15
102	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. <i>CNS Oncology</i> , 2022, 11, CNS87.	1.2	15
103	Drug sequestration in cytoplasmic organelles does not contribute to the diminished sensitivity of anthracyclines in multidrug resistant K562 cells. <i>FEBS Journal</i> , 2001, 268, 4459-4467.	0.2	14
104	Simple, semiautomatic assay of cytostatic and cytotoxic effects of antitumor drugs by laser scanning cytometry: Effects of the bis-intercalator WP631 on growth and cell cycle of T-24 cells. <i>Cytometry</i> , 2004, 57A, 113-119.	1.8	14
105	DFT Study on the Selectivity of Complexation of Metal Cations with a Dioxadithia Crown Ether Ligand. <i>Journal of Physical Chemistry A</i> , 2008, 112, 13633-13640.	1.1	14
106	Development of novel molecular probes of the Rio1 atypical protein kinase. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 1292-1301.	1.1	14
107	The 4-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. <i>Investigational New Drugs</i> , 2006, 25, 115-122.	1.2	13
108	A Bisanthracycline (WP631) Represses uPAR Gene Expression and Cell Migration of RKO Colon Cancer Cells by Interfering With Transcription Factor Binding to a Chromatin-Accessible \sim 148/ \sim 124 Promoter Region. <i>Oncology Research</i> , 2005, 15, 265-279.	0.6	13

#	ARTICLE	IF	CITATIONS
109	Structure and biological activity of cationic [PtLCl(DMSO)]NO ₃ ·DMSO complex containing a chelated diaminosugar: methyl-3,4-diamino-2,3,4,6-tetra-deoxy-β-D-lyxopyranoside. <i>European Journal of Medicinal Chemistry</i> , 2003, 38, 775-780.	2.6	11
110	Sequence selective binding of bis-daunorubicin WP631 to DNA. <i>FEBS Journal</i> , 2004, 271, 3556-3566.	0.2	11
111	Novel molecular multilevel targeted antitumor agents. <i>Cancer Translational Medicine</i> , 2017, 3, 69.	0.2	11
112	Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1403-10.	1.9	11
113	Liposomal formulation and antitumor activity of 14-O-palmitoyl-hydroxyrubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 267-271.	1.1	10
114	Synthesis and antitumor activity of anthracycline disaccharide glycosides containing daunosamine.. <i>Journal of Antibiotics</i> , 1993, 46, 1720-1730.	1.0	10
115	Comparison of DNA sequence selectivity of anthracycline antibiotics and their 3-hydroxylated analogs. <i>Chemico-Biological Interactions</i> , 1996, 100, 165-176.	1.7	10
116	A new approach to 2-deoxyglycosides permitting access to anthracycline glycosides specifically labeled at the 2-position. <i>Carbohydrate Research</i> , 1989, 187, 149-153.	1.1	9
117	One step C-acylation of glycals and 2-deoxy-hexopyranoses at C-2. <i>Tetrahedron Letters</i> , 1992, 33, 7681-7684.	0.7	9
118	Substitutions at C2' of Daunosamine in the Anticancer Drug Daunorubicin Alter Its DNA-Binding Sequence Specificity. <i>FEBS Journal</i> , 1996, 240, 331-335.	0.2	9
119	WP744 is a novel anthracycline with enhanced activity against neuroblastoma1. <i>Journal of Surgical Research</i> , 2004, 121, 187-196.	0.8	9
120	New adriamycin analogs. Synthesis and antitumor activity of 14-substituted 7-O-(3,4-di-O-acetyl-2,6-dideoxy-α-L-lyxo-hexopyranosyl)daunomycinones.. <i>Journal of Antibiotics</i> , 1981, 34, 1019-1025.	1.0	8
121	Complexation of Metal Ions in Langmuir Films Formed with Two Amphiphilic Dioxadithia Crown Ethers. <i>Journal of Physical Chemistry B</i> , 2008, 112, 10953-10963.	1.2	8
122	Formation and Reactions of Glycal Derivatives. , 2001, , 749-783.		8
123	Maximizing Local Access to Therapeutic Deliveries in Glioblastoma. Part I: Targeted Cytotoxic Therapy. , 0, , 341-358.		8
124	Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells. <i>Anticancer Research</i> , 2005, 25, 2193-8.	0.5	8
125	Preparation of 4-O-acetyl-1,5-anhydro-2,3,6-trideoxy-3-trifluoroacetamido-β-L-lyxo-hex-1-enitol, a key intermediate in synthesis of daunosamine glycosides. <i>Carbohydrate Research</i> , 1989, 187, 145-148.	1.1	7
126	3'-Hydroxyesorubicin. Synthesis and antitumor activity.. <i>Journal of Antibiotics</i> , 1990, 43, 838-846.	1.0	7

#	ARTICLE	IF	CITATIONS
127	The influence of stereoselective P-glycoprotein- and multidrug resistance-associated protein-mediated transport of daunorubicin11 Abbreviations: P-gp, P-glycoprotein; MRP1, multidrug resistance-associated protein; DNR, daunorubicin; WP900, daunorubicin enantiomer; Ci, intracellular free drug concentration in the cytosol; Ce: extracellular free drug concentration; Cn1, overall concentration of drug accumulated inside the cell (in the nucleus and in the acidic compartment); Cn, overall concentration of drug bound. <i>Biochemical Pharmacology</i> , 2001, 62, 561-567.	2.0	7
128	Glycol Derivatives. , 2008, , 699-735.		7
129	Drug Conjugates for Targeting Eph Receptors in Glioblastoma. <i>Pharmaceuticals</i> , 2020, 13, 77.	1.7	7
130	Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model. <i>Biomedicines</i> , 2021, 9, 1749.	1.4	7
131	14-Esters of 7-O-(3,4-di-O-acetyl-2,6-dideoxy- α -L-lyxo-hexopyranosyl)adriamycinone: synthesis and antitumor activity.. <i>Journal of Antibiotics</i> , 1983, 36, 1211-1215.	1.0	6
132	Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells. <i>International Journal of Cancer</i> , 1995, 61, 402-408.	2.3	6
133	3'-Hydroxyesorubicin halogenated at C-2'.. <i>Journal of Antibiotics</i> , 1992, 45, 386-393.	1.0	5
134	Quantitative Analysis of the Lipophilic Doxorubicin Analogue Annamycin in Plasma and Tissue Samples by Reversed-Phase Chromatography. <i>Journal of Pharmaceutical Sciences</i> , 1993, 82, 1151-1154.	1.6	5
135	Synthesis of 3-deoxyaldulosonic acid esters by one-carbon chain extension of glycol-derived lactone precursors. <i>Carbohydrate Research</i> , 1993, 246, 105-118.	1.1	5
136	WP760, a melanoma selective drug. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 625-633.	1.1	5
137	Structure and dynamics of methyl cis-3,4-diamino-2,3,4,6-tetra-deoxy- β -L-lyxo-hexopyranoside complexes with PtCl ₂ and PdCl ₂ , by ¹ H, ² H, ¹³ C, ¹⁵ N and ¹⁹⁵ Pt NMR spectroscopy in DMSO, CD ₃ CN and H ₂ O. <i>Dalton Transactions</i> , 2008, , 4129.	1.6	5
138	Bromine Atom Interactions in Biologically Active Acrylamide Derivatives. <i>Crystal Growth and Design</i> , 2015, 15, 2632-2642.	1.4	5
139	Experimental and Computational Studies on Structure and Energetic Properties of Halogen Derivatives of 2-Deoxy-D-Glucose. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3720.	1.8	5
140	Topoisomerase II alpha expression and cytotoxicity of anthracyclines in human neoplastic cells. <i>Acta Poloniae Pharmaceutica</i> , 2006, 63, 15-8.	0.3	5
141	Preparative procedures for conversion of daunorubicin into doxorubicin (Adriamycin) and 14-O-acetyldoxorubicin by way of 14-bromodaunorubicin. <i>Carbohydrate Research</i> , 1988, 184, 231-235.	1.1	4
142	Synthesis of new 1-C-(2-furyl)- and 3-C-(2-furyl)-hexopyranosides and 3-C-(2-furyl)-daunorubicin analogs. <i>Monatshefte für Chemie</i> , 1991, 122, 419-423.	0.9	4
143	Multidrug resistance protein functionality: no effect of intracellular or extracellular pH changes. <i>Biochemical Pharmacology</i> , 2000, 60, 1485-1489.	2.0	4
144	The Ability of New Sugar-Modified Derivatives of Antitumor Anthracycline, Daunorubicin, to Stimulate NAD(P)H Oxidation in Different Cellular Oxidoreductase Systems: NADH Dehydrogenase, NADPH Cytochrome P450 Reductase, and Xanthine Oxidase. <i>Oncology Research</i> , 2004, 14, 469-474.	0.6	4

#	ARTICLE	IF	CITATIONS
145	Autophagy modulates the effects of bisanthracycline WP 631 on p53-deficient prostate cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 786-798.	1.6	4
146	Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. <i>Blood</i> , 2005, 106, 1489-1489.	0.6	4
147	Activation of a Novel Proteasomal Independent Bcr/Abl Degradation Pathway by WP1130 Induces Apoptosis in CML Cells. <i>Blood</i> , 2005, 106, 2862-2862.	0.6	4
148	Changes in gene expression induced by Sp1 knockdown differ from those caused by challenging Sp1 binding to gene promoters. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2011, 1809, 327-336.	0.9	3
149	Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation. <i>Investigational New Drugs</i> , 2017, 35, 545-555.	1.2	3
150	WP-1034, a Novel Jak-Stat Inhibitor, Has Proapoptotic and Antileukemic Activity in Acute Myeloid Leukemia (AML) Cell Lines and AML Patient Samples. <i>Blood</i> , 2004, 104, 2528-2528.	0.6	3
151	The effect of new anthracycline derivatives on the induction of apoptotic processes in human neoplastic cells. <i>Folia Histochemica Et Cytobiologica</i> , 2004, 42, 127-30.	0.6	3
152	X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-D-glucose in solid state and solution. <i>RSC Advances</i> , 2022, 12, 8345-8360.	1.7	3
153	Non-Cross-Resistant Anthracyclines with Reduced Basicity and Increased Stability of the Glycosidic Bond. <i>ACS Symposium Series</i> , 1994, , 14-46.	0.5	2
154	Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia. <i>Blood</i> , 2004, 104, 2964-2964.	0.6	1
155	WP-1066, a Next-Generation Member of JAK-Stat Inhibitors, Induces Cell Cycle Arrest, Abrogates Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells. <i>Blood</i> , 2004, 104, 1169-1169.	0.6	1
156	The Use of Liposomes as Carriers of Lipophilic Anthracycline Antibiotics. <i>Journal of Liposome Research</i> , 1994, 4, 555-573.	1.5	0